Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer

References

• Groarke A, Curtis R, Skelton J, et al. Quality of life and adjustment in men with prostate cancer: interplay of stress, threat and resilience. PloS One. 2020;15(9):e0239469.
   PubMed Web of Science ®Google Scholar
• Marra G, Valerio M, Heidegger I, et al. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review. Eur Urol Oncol. 2020;3(5):565–581.
   PubMed Web of Science ®Google Scholar
• Thüring M, Knuchel R, Picchetta L, et al. The prognostic value of Indoleamine-2,3-dioxygenase gene expression in urine of prostate cancer patients undergoing radical prostatectomy as first treatment of choice. Front Immunol. 2020;11:1244.
   PubMed Web of Science ®Google Scholar
• Shao L, Yan Y, Liu Z, et al. Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy. Theranostics. 2020;10(22):10200–10212.
   PubMed Web of Science ®Google Scholar
• Goldberg H, Glicksman R, Woon D, et al. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer? BJU Int. 2020. DOI:10.1111/bju.15236
   Google Scholar
• Bartkowiak D, Thamm R, Siegmann A, et al. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. Radiother Oncol. 2020;154:255–259.
   PubMed Web of Science ®Google Scholar
• Ricco A, Mukhopadhyay N, Deng X, et al. Moderately hypofractionated intensity modulated radiation therapy with simultaneous integrated boost for prostate cancer: five-year toxicity results from a prospective phase I/II Trial. Front Oncol. 2020;10:1686.
   PubMed Web of Science ®Google Scholar
• Daisley B, Chanyi R, Abdur-Rashid K, et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020;11(1):4822.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Anton A, Shapiro J, et al. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. Asia Pac J Clin Oncol. 2020;38:78.
   Google Scholar
• Seifert R, Kessel K, Schlack K, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2020. DOI:10.1007/s00259-020-05040-1
   Web of Science ®Google Scholar
• Thibord F, Munsch G, Perret C, et al. Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis. Eur Heart J Suppl. 2020;22:C34–C45.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu L, Jin Y, et al. Identification of key miRNAs in papillary thyroid carcinoma based on data mining and bioinformatics methods. Biomed Rep. 2020;12(1):11–16.
   PubMed Web of Science ®Google Scholar
• Liu J, Yu J, Jiang W, et al. Targeting of CDKN1B by miR-222-3p may contribute to the development of intervertebral disc degeneration. FEBS Open Bio. 2019;9(4):728–735.
   PubMed Web of Science ®Google Scholar
• Nejad C, Pillman K, Siddle K, et al. miR-222 isoforms are differentially regulated by type-I interferon. RNA. 2018;24(3):332–341.
   PubMed Web of Science ®Google Scholar
• Coarfa C, Fiskus W, Eedunuri V, et al. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. 2016;35(18):2345–2356.
   PubMed Web of Science ®Google Scholar
• Mattie M, Benz C, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24.
   PubMed Web of Science ®Google Scholar
• Liao G, Xiong H, Tang J, et al. MicroRNA-92a inhibits the cell viability and metastasis of prostate cancer by targeting SOX4. Technol Cancer Res Treat. 2020;19:1533033820959354.
   Web of Science ®Google Scholar
• Zhang Q, Yang X, Luo L, et al. Targeted p21 activation by a new double stranded RNA suppresses human prostate cancer cells growth and metastasis. Am J Transl Res. 2020;12(8):4175–4188.
   PubMed Web of Science ®Google Scholar
• Sun F, Wu K, Yao Z, et al. Long Noncoding RNA PVT1 Promotes Prostate Cancer Metastasis by Increasing NOP2 Expression via Targeting Tumor Suppressor MicroRNAs. Onco Targets Ther. 2020;13:6755–6765.
   PubMed Web of Science ®Google Scholar
• Peng Y, Li Y, Li Y, et al. HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer. Aging (Albany NY). 2020;12(19):19375–19398.
   PubMedGoogle Scholar
• Jiang K, Li G, Chen W, et al. Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas. Onco Targets Ther. 2020;13:1311–1319.
   PubMed Web of Science ®Google Scholar
• Lyu J, Zhu Y, Zhang Q. An increased level of MiR-222-3p is associated with TMP2 suppression, ERK activation and is associated with metastasis and a poor prognosis in renal clear cell carcinoma. Cancer Biomarkers. 2020;28(2):141–149.
   PubMed Web of Science ®Google Scholar
• Wei F, Ma C, Zhou T, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer. 2017;16(1):132.
   PubMedGoogle Scholar
• Fan L, Lei H, Zhang S, et al. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10. Theranostics. 2020;10(13):5895–5913.
   PubMed Web of Science ®Google Scholar
• Mercatelli N, Coppola V, Bonci D, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PloS One. 2008;3(12):e4029.
   PubMed Web of Science ®Google Scholar
• Sun T, Wang Q, Balk S, et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69(8):3356–3363.
   PubMed Web of Science ®Google Scholar
• Sun T, Du S, Armenia J, et al. Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis. 2018;7(3):30.
   PubMedGoogle Scholar
• Fredsøe J, Rasmussen A, Mouritzen P, et al. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine. Int J Cancer. 2019;145(9):2558–2567.
   PubMed Web of Science ®Google Scholar
• Sapre N, Hong M, Macintyre G, et al. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PloS One. 2014;9(4):e91729.
   PubMed Web of Science ®Google Scholar
• Goto Y, Kojima S, Nishikawa R, et al. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer. 2015;113(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• Valera V, Parra-Medina R, Walter B, et al. microRNA expression profiling in young prostate cancer patients. J Cancer. 2020;11(14):4106–4114.
   PubMed Web of Science ®Google Scholar
• Krebs M, Solimando A, Kalogirou C, et al. miR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro. J Clin Med. 2020;9(3):670.
   Web of Science ®Google Scholar
• Liu Y, Wang G, Jiang X, et al. TRIM67 inhibits tumor proliferation and metastasis by mediating in Colorectal Cancer. J Cancer. 2020;11(20):6025–6037.
   PubMed Web of Science ®Google Scholar
• Liu D, Xiao P, Feng C, et al. Long non-coding RNA GASL1 restrains gastric carcinoma cell proliferation and metastasis by sponging microRNA-106a. Cell Cycle. 2020;19:2611–2621
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng Z, Qiao L, et al. Semaphorin 4C promotes macrophage recruitment and angiogenesis in breast cancer. Mol Cancer Res. 2019;17(10):2015–2028.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu B, Tian Y, et al. P53 Mutant p53 regulates cancer-associated fibroblasts properties through Stat3 pathway. Onco Targets Ther. 2020;13:1355–1363.
   PubMed Web of Science ®Google Scholar
• Ryan T. A pre-synaptic to-do list for coupling exocytosis to endocytosis. Curr Opin Cell Biol. 2006;18(4):416–421.
   PubMed Web of Science ®Google Scholar
• Clifford R, Maryon E, Kaplan J. Dynamic internalization and recycling of a metal ion transporter: cu homeostasis and CTR1, the human Cu⁺ uptake system. J Cell Sci. 2016;129(8):1711–1721.
   PubMed Web of Science ®Google Scholar
• Yemni E, Monies D, Alkhairallah T, et al. Integrated analysis of whole exome sequencing and copy number evaluation in Parkinson’s disease. Sci Rep. 2019;9(1):3344.
   PubMedGoogle Scholar
• Koo S, Kochlamazashvili G, Rost B, et al. Vesicular Synaptobrevin/VAMP2 levels guarded by AP180 control efficient neurotransmission. Neuron. 2015;88(2):330–344.
   PubMed Web of Science ®Google Scholar
• Takata A, Matsumoto N, Kato T. Genome-wide identification of splicing QTLs in the human brain and their enrichment among schizophrenia-associated loci. Nat Commun. 2017;8:14519.
   PubMed Web of Science ®Google Scholar
• Shang D, Liu Y, Zhang J, et al. Peroxisome proliferator-activated receptor γ (PPARγ) suppresses the proliferation and metastasis of patients with urothelial carcinoma after renal transplantation by inhibiting LEF1/β-catenin signaling. Bioengineered. 2020;11(1):1350–1367.
   PubMed Web of Science ®Google Scholar
• Cao Y, Xiao Y, Ravid R, et al. Changed clathrin regulatory proteins in the brains of Alzheimer’s disease patients and animal models. J Alzheimers Dis. 2010;22(1):329–342.
   PubMed Web of Science ®Google Scholar
• Pan F, Chen M, Song X, et al. MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments. Anticancer Drugs. 2020;31(4):411–422.
   PubMed Web of Science ®Google Scholar
• Gao Y, Mao X, Zhu T, et al. COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget. 2016;7(43):70494–70503.
   PubMedGoogle Scholar